Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints... see more

NDAQ:APHA - Post Discussion

Aphria Inc. > Tough Day
View:
Post by skyplt on Apr 12, 2021 4:25pm

Tough Day

I am not nearly as deep as I used to be, but a 14 percent decline no matter how much you own is tough to watch. I guess it remains to be seen what the analysts will do. I am particularly interested in Zamparo's revised assessment, if any. As much as I disliked some of his calls over the last couple of years, he has been relatively accurate. Hopefully CIBC retains 28CDN (which is what my sell order is set at...not being on margin, not needing the money, and not having it all on APHA makes for less long term angst). I still believe the story is not over for APHA. This time last year when we were complaining about the stock price Mr. Simon was in the midst of talks with SweetWater and Tilray. Perhaps it is wishful thinking, but I believe in the Irwin/Carl duo and see APHA as the cannabis holding to have in a balanced portfolio. I am neither buying or selling at this time, just holding onto the shares I have as I believe in the long term prospects. That being said...ghost, you were right, but...there is being right and then there is being an a$$hole about it. Not sure how necessary it was to brow beat some here who are obviously hurting. A lesson was taught by you, but you had the opportunity to educate without humiliation. I do have an understanding of candlesticks, Bollinger Bands, and RSI and did not see negative 14 percent coming. To be fair, I did think Stifel raised a few salient points regarding decreased sales. I did not predict, but felt we would come in around 160 to 170M. I was wrong. If I knew what was in store I would have sold while marginally in the green on Friday. That being said, I am more fundamentals than technicals. I have had the privilege of direct communication with both Mr. Simon and Mr. Merton. They are not only good at what they do, but they are good people. That has been a bit of a rarity in this sector. All the best to each of you. We are all attempting to navigate a very mercurial sector. Better days I hope.
Comment by Medicalcan on Apr 12, 2021 5:08pm
https://m.investing.com/news/cibc-stick-to-their-buy-rating-for-aphria-2472067
Comment by CaneIsAbel on Apr 12, 2021 5:15pm
I love reading your posts. I thought 170-180 as well. With that being I just watched Irwin on CNBC. I'm not phased just surprised when I should have been prepared. I didn't see 15 percent. No one did. 
Comment by ellgar on Apr 12, 2021 7:09pm
Good post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities